1292211-41-6

Upstream product

• 1292211-39-2 methyl 8-(benzyloxy)-5-(4-(4-(tert-butoxycarbonylamino)butyl)-piperazin-1-yl)-1,6-naphthyridine-7-carboxylate 
• 1292211-00-7 methyl 8-(benzyloxy)-5-bromo-1,6-naphthyridine-7-carboxylate 
• 1292211-08-5 methyl 8-(benzyloxy)-5-(piperazin-1-yl)-1,6-naphthyridine-7-carboxylate 
• 1292211-02-9 2-(aminomethyl)-5-fluorobenzoic acid ethyl ester hydrochloride 
• 1292211-40-5 8-(benzyloxy)-5-(4-(4-(tert-butoxycarbonylamino)butyl)piperazin-1-yl)-1,6-naphthyridine-7-carboxylic acid 
• 410544-37-5 5-bromo-8-hydroxy-[1,6]naphthyridine-7-carboxylic acid methyl ester 
• 100-39-0 benzyl bromide 

Downstream Products

• 1292211-44-9 2-((5-(4-(4-aminobutyl)piperazin-1-yl)-8-hydroxy-1,6-naphthyridine-7-carboxamido)methyl)-5-fluorobenzoic acid trifluoroacetic acid 

Relevant academic research and scientific papers

Medicine for treating cholecystitis and preparation method thereof

The invention relates to a medicine for treating cholecystitis and a preparation method thereof. Specifically, the medicine is prepared from 2-((8- (benzyloxy)-5-(4-(4-(tert-butoxycarbonylamino) butyl) piperazine-1-yl)-1, 6-naphthyridine- 7-formylamino) methyl)-5-fluorobenzoic acid ethyl ester and a pharmaceutically acceptable carrier. The invention also relates to a preparation method of the medicine and application of the compound in preparation of a medicine for treating cholecystitis.

Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus

This invention concerns to naphthyridin derivatives of formula (I) for use in the treatment or prevention of feline immunodeficiency virus (FIV). Furthermore the present invention relates to a method of treating or preventing infection of feline immunodeficiency virus in a feline animal wherein said method comprises the administration to said feline animal of a therapeutically effective amount of a naphthyridin derivative.

MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS

This invention concerns to naphthyridin derivatives of formula (I) for use in the treatment or prevention of feline immunodeficiency virus (FIV). Furthermore the present invention relates to a method of treating or preventing infection of feline immunodeficiency virus in a feline animal wherein said method comprises the administration to said feline animal of a therapeutically effective amount of a naphthyridin derivative.